Rationally Designed Ir(III) Complex with an Exceptionally Strong Binding to Human Serum Albumin for Targeted Photodynamic Therapy DOI
Antonio Linero-Artiaga,

Lisa-Marie Servos,

Venancio Rodrı́guez

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

The application of iridium(III) complexes in photodynamic therapy (PDT) is often limited by their poor selectivity for cancerous cells, necessitating high drug doses that increase the risk side effects. development efficient delivery systems such as albumin conjugation therefore crucial to enhance tumor-targeted photosensitizers. To date, vast majority metal exhibit weak moderate binding with human serum albumin, limiting feasibility this approach. overcome limitation, rational design through molecular docking and density functional theory calculations a novel Ir(III) complex strong albumin-binding photosensitizer described. herein reported compound has highest constant ever an iridium complex, it showed photocatalytically produce reactive oxygen species upon blue light irradiation. presented well structural derivatives could have potential therapy.

Language: Английский

Intracellular Photocatalytic NADH/NAD(P)H Oxidation for Cancer Drug Development DOI
Ashish Yadav, Samya Banerjee,

Arif Ali Mandal

et al.

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: 147(9), P. 7161 - 7181

Published: Feb. 20, 2025

Photocatalytic cancer therapy (PCT) has emerged as a cutting-edge anticancer mechanism of action, harnessing light energy to mediate the catalytic oxidation intracellular substrates. PCT is significant current importance due its potential address limitations conventional chemotherapy, particularly drug resistance and side effects. This approach offers noninvasive, targeted treatment option by utilizing metal-based photocatalysts induce redox metabolic disorders within cells. The disrupt cell metabolism converting NADH/NAD(P)H NAD+/NAD(P)+ via photoredox processes, altering NAD+/NADH or NAD(P)+/NAD(P)H ratios, which are crucial for cellular metabolism. Ir(III), Ru(II), Re(I), Os(II) demonstrated promising efficacy. Despite these developments, gaps remain in literature translating this new into clinical trials. Perspective critically examines developments research area provides future directions designing efficient PCT.

Language: Английский

Citations

0
Rationally Designed Ir(III) Complex with an Exceptionally Strong Binding to Human Serum Albumin for Targeted Photodynamic Therapy DOI
Antonio Linero-Artiaga,

Lisa-Marie Servos,

Venancio Rodrı́guez

et al.

Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

The application of iridium(III) complexes in photodynamic therapy (PDT) is often limited by their poor selectivity for cancerous cells, necessitating high drug doses that increase the risk side effects. development efficient delivery systems such as albumin conjugation therefore crucial to enhance tumor-targeted photosensitizers. To date, vast majority metal exhibit weak moderate binding with human serum albumin, limiting feasibility this approach. overcome limitation, rational design through molecular docking and density functional theory calculations a novel Ir(III) complex strong albumin-binding photosensitizer described. herein reported compound has highest constant ever an iridium complex, it showed photocatalytically produce reactive oxygen species upon blue light irradiation. presented well structural derivatives could have potential therapy.

Language: Английский

Citations

0